![]() |
18th May 2008 @ 12:40pm |
| Subscribe | Instructions To Authors | Advertising/Supplements | Contact Us | Help |
|
Volume 1, Number 2, October 2004POPULAR Diabetes Vasc Dis Res 2004;1:67. POPULAR Individuals with insulin resistance are at increased risk of glucose intolerance, dyslipidaemia and essential hypertension. In 1988, it was proposed that this cluster of abnormalities associated with insulin resistance identifies individuals at increased risk for cardiovascular disease. Recently, in an effort to raise awareness of this problem, both the World Health Organisation (WHO) and the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program have suggested a set of clinical criteria to diagnose individuals with what they both refer to as the metabolic syndrome. Although using the same term, the two groups have different goals for creating this diagnosis and different criteria to identify individuals, which relate to their different institutional goals. This review critically evaluates the similarities and differences between the two groups’ concepts of the metabolic syndrome and questions the clinical utility of making the diagnosis with either set of definitions. Diabetes Vasc Dis Res 2004;1:68-75. POPULAR Over the past few years it has been recognised that insulin resistance (IR) is an independent risk factor for major cardiovascular events. In addition, IR is associated with other factors such as hypertension, dyslipidaemia and endothelial dysfunction, and this cluster of metabolic disorders contributes to the cardiovascular risk of patients with IR. Given the increasing number of patients with IR, the modulation of their cardiovascular risk is a major task in diabetology and vascular medicine. This review will focus on the role of IR as a cardiovascular risk factor and on the potential of activators of the nuclear transcription factor peroxisome proliferator-activated receptor gamma (PPARγ) to modulate these risk factors associated with IR. Diabetes Vasc Dis Res 2004;1:76-81. ORIGINAL PAPEREffects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes Background:
Improvement in vascular endothelial function is widely cited as a beneficial effect of hormone replacement therapy (HRT). Women with type 2 diabetes (T2DM) are at increased cardiovascular risk and have impaired endothelial function. Any benefits of HRT on endothelial function in this group are of particular interest. Diabetes Vasc Dis Res 2004;1:82-88. ORIGINAL PAPEREnhanced left ventricular systolic function early in type 2 diabetic mice: clinical implications It is unclear whether the increase in availability of substrates for energy production in diabetes can lead to enhanced systolic function early in the disease, before the onset of structural changes to the myocardium. To examine this issue, BKS.Cg-m +/+ Lepr db (db/db) mice with type 2 diabetes and wild type controls had left ventricular pressure-volume relationships determined in situ. We demonstrated that the db/db mice, when compared to their wild type controls, generated greater left ventricular pressure and an enhancement of left ventricular systolic function based on enhanced power/EDV, positive dP/dt, preload recruitable stroke work, dP/dt – EDV relationship, and curvilinear end-systolic elastance. This enhancement in systolic function occurred despite the db/db mice having greater body weight, but similar preload (end-diastolic volume) and afterload (effective arterial elastance). Diabetes Vasc Dis Res 2004;1:89-94. |